Research groups

GC03 Infectious Diseases

The Infectious Diseases Group (GC-03) is a consolidated and interdisciplinary group that includes biologists, immunologists, research nurses and infectious diseases specialists. We focus on the study of several infectious pathologies. Through the study of pathogens and host immune responses, we aim to improve our understanding and the treatment and prevention of infectious diseases.

Our research expertise lies in the study of infection and host immunological responses that lead to the control and/or eradication of the infectious pathogen. By understanding the mechanisms of development and transmission of infectious diseases, we can provide a rational basis for the development of novel or better treatments, therapies and preventative measures to combat disease.

Our research areas include:

  • Immunobiology and pathogenesis of infectious diseases, primarily infections caused by citomegalovirus in transplant recipients.
  • Prevention, control and treatment of infections caused by multidrug-resistant Gram-negative bacteria.
  • Clinical-epidemiological studies, including clinical trials, aimed at characterizing risk factors, clinical features and the efficacy/safety of new treatments for infectious diseases.

Our research starts with the identification of a clinical problem that we try to solve using an experimental approach. The aim is that our experimental results have an impact on healthcare solutions and improve disease prognosis (translational research). Our strategy is to develop quality research focused on the most prevalent health problems, and with high clinical applicability.

Our research contributes to the Programs “Antimicrobial Resistance” and “Infections in Transplanted Patients” of the Spanish Network for Research in Infectious Diseases (REIPI, http://reipi.org/)  supported by the  Institute of Health Carlos III  (ISCIII). Our group has extensive multinational collaborative research. We also aim at establishing consolidated relationships with other groups in Europe and to obtain research funding within the H2020 framework programme. In addition, we consider important to support the training of new researchers and the stabilization of postdoctoral researchers in our group.

Our people

The Infectious Diseases Group is a consolidated and interdisciplinary group that includes biologists, immunologists, research nurses and infectious diseases specialists.

Leadership

  • Professor Julián de la Torre Cisneros, Professor of Medicine and Head of Infectious Diseases Unit at Reina Sofía University Hospital in Córdoba.
  • Dr. Sara Cantisán, PhD in Biology. Inmunology.specialist.
  • Dr. Elena Pérez-Nadales, PhD in Biology. Genetic specialist.
  • Dr. Juan José Castón, MD, PhD in Medicine. Infectious Diseases specialist.
  • Dr. Elisa Vidal, MD, PhD in Medicine. Infectious Diseases specialist.
  • Dr. Clara Natera, MD, PhD in Medicine. Infectious Diseases specialist.

Predoctoral researchers

  • Aurora Páez-Vega, MSc
  • Angela Cano, MD, MSc
  • Alejandra M. Natera, MSc 
  • Jorge Valle Arroyo, MSc

Laboratory technicians

  • Ana Salinas

Data managers

  • Julián Torre Giménez
  • Lara Kindelán, BSc

Research nurses

  • Azahara Frutos
  • Manuel Recio Rufian

Administrative staff

  • Teresa Añón 
  • Inmaculada Cantueso

Research Lines

This line of research includes several ongoing projects, focused on several infectious pathologies affecting transplanted patients, both solid organ and hematopoietic progenitor transplant recipients.

The specific objectives are:

  • To evaluate the efficacy of reduced prophylaxis followed by immuno-guided prophylaxis to prevent CMV disease in low-risk lung transplant recipients in comparison with the usual strategy of universal prophylaxis.
  • To analyze the impact of the lack of CMV-specific cellular immunity in CMV-seropositive hematopoietic progenitors donors on the incidence / severity of CMV replication in the recipients.
  • To study the spontaneous resolution of CMV replication in transplant patients who have pretransplant CMV-specific cellular immunity.
  • To determine the safety and efficacy of discontinuing valganciclovir prophylaxis in CMV-seropositive renal transplant recipients who receive thymoglobulin but maintain the CMV-specific immunity.
  • To establish the association between polymorphisms in cytokine genes and the risk of CMV reactivation in low risk patients.
  • To collaborate with the multi-center projects of the joint strategic plan of REIPI - Spanish Network for Research on Infectious Diseases.
  • To obtain funding for new research projects that give continuity to the research line.
  • Reducing the incidence and mortality of severe infections caused by carbapenem-resistant Klebsiella pneumoniae.
  • Improving the management of bloodstream infections caused by extended-spectrum and carbapenemase-producing Enterobacterales in solid organ transplant patients (INCREMENT-SOT Project, ClinicalTrials.gov Identifier: NCT02852902)
  • Clinical efficacy of the new cephalosporin/β-Lactamase inhibitor, ceftazidime/avibactam, versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacterales in patients with a range of underlaying conditions (hematologic patients and solid-organ transplant recipients and general population)
  • Participation in REJUVENATE, a Phase II, pharmacokinetic and safety study of whose primary objective is to test aztreonam-avibactam (ATM-AVI) as a treatment for hospitalized patients with a complicated intra-abdominal infection. 
  • Collaborating with the multi-center projects of the joint strategic plan of REIPI - Spanish Network for Research on Infectious Diseases

Networks

    REIPI - Spanish Networ for Research in Infectious Diseases. (Red Española de Investigación en Patología Infecciosa).Coordinator at Reina Sofía University Hopsital: Prof. Dr. Julián de la Torre Cisneros.

    COMBACTE-NET (combatting bacterial resistance in Europe – networks), Project ID: 115523.

    COMBACTE-CARE (combatting bacterial resistance in Europe – carbapenem-resistence), Project ID: 115620.

    INCREMENT-SOT, an international consortium for the clinical study of blood stream infections caused by multi-drug resistant Enterobacterales in solid organ transplantation (SOT). We promote and coordinate this international network, which includes 40 centers specialized in SOT from 16 countries worldwide.

    PROACTIVE group: Optimization in the use of antibiotics and treatment of complex bacterial infections caused by resistant strains, Ministry of Health, Junta de Andalucía. File: AC-0044-2013. Principal Investigator: Jesús Rodríguez Baño (Hospital Virgen Macarena). PI at Reina Sofía University Hospital: Julián de la Torre Cisneros.

    PAIDI CTS-647 Scientific Group. Coordinator of the Group "Translational Research in Infectious Diseases" that belongs to the Andalusian Research Plan (PAI CTS647), since July 2009.

Keywords

  • cytomegalovirus
  • multidrug-resistant microorganisms
  • immunopathology
  • transplantation
  • specific immune response

Additional Information

HIGHLIGHTED PUBLICATIONS BY THE INFECTIOUS DISEASES UNIT 2014-2018

González-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, Natera C, Rodríguez M, Salcedo I, Rodríguez-López F, Rivero A, Rodríguez-Baño J. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015 Mar; 70(3):905-13. doi: 10.1093/jac/dku432. PMID: 25344809
IF: 4.919
Q: 1  D: 2

Cantisán S, Rodelo-Haad C, Páez-Vega A, Nieto A, Vaquero JM, Poyato A, Montejo M, Fariñas MC, Rivero A, Solana R, Martín-Malo A, Torre-Cisneros J. Factors Related to the Development of CMV-Specific CD8þ T cell Response in CMV-Seropositive Solid Organ Transplant Candidates. Am J Transplant. 2015 Mar; 15(3):715-22.   doi: 10.1111/ajt.13012. Epub 2015 Feb 3. PMID: 25648131
IF: 5.569
Q: 1  D: 1

Clemente W, Vidal E, Girão E, Ramos AS, Govedic F, Merino E, Muñoz P, Sabé N, Cervera C, Cota GF, Cordero E, Mena A, Montejo M, López-Medrano F, Aguado JM, Fernandes P, Valerio M, Carratalá J, Moreno A, Oliveira J, Mourão PH, Torre-Cisneros J. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect. 2015 Jan; 21(1):89-95.  doi: 10.1016/j.cmi.2014.09.002. Epub 2014 Oct 12. PMID: 25636932
IF: 4.575
Q: 1  D: 2

Gracia-Ahufinger I, Ferrando-Martínez S, Montejo M, Muñoz-Villanueva MC, Cantisán S, Rivero A, Solana R, Leal M, Torre-Cisneros J. Pre-transplant thymic function is associated with the risk of cytomegalovirus disease after solid organ transplantation. Clin Microbiol Infect. 2015 May; 21(5):511.e1-7. doi: 10.1016/j.cmi.2014.12.020. Epub 2015 Jan 14. PMID: 25682299
IF: 4.575
Q: 1  D: 2

Torre-Cisneros J, Juan RS, Rosso-Fernández CM, Silva JT, Muñoz-Sanz A, Muñoz P, Miguez E, Martín-Dávila P, López-Ruz MA, Vidal E, Cordero E, Montejo M, Blanes M, Fariñas C, Herrero JI, Rodrigo J, Aguado JM. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: Safety analysis of a multicenter randomized trial. Clin Infect Dis. 2015 Jun 1; 60(11):1642-9. doi: 10.1093/cid/civ156. Epub 2015 Feb 25. PMID: 25722196
IF: 8.736
Q: 1  D: 1

Castón JJ, Castells L, Varo E, Gómez MA, de la Mata M, Campos-Varela I, Lumbreras C, González-Dieguez L, Fabregat J, Herrero I, Salcedo M, Sánchez-Antolín G, Torre-Cisneros J. Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation. Transplantation. 2016 Mar; 100(3):593-599. PMID: 26371595
IF: 3.690
Q: 1  D: 1

Castón JJ, Cantisán S, González-Gasca F, Páez-Vega A, Abdel-Hadi H, Illescas S, Alonso G, Torre-Cisneros J. Interferon-γ production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients. Intensive Care Med. 2016 Jan; 42(1):46-53. doi: 10.1007/s00134-015-4077-6. Epub 2015 Nov 4. PMID: 26537489
IF: 10.125
Q: 1  D: 1

Cantisán S, Páez-Vega A, Pérez-Romero P, Montejo M, Cordero E, Gracia-Ahufinger I, Martín-Gandul C, Maruri N, Aguado R, Solana R, Torre-Cisneros J; Spanish Network for Research in Infectious Diseases (REIPI). Prevention strategies differentially modulate the impact of cytomegalovirus replication on CD8 (+) T-cell differentiation in high-risk solid organ transplant patients. Antiviral Res. 2016 Aug; 132: 244-51. doi: 10.1016/j.antiviral.2016.06.012. Epub 2016 Jul 1. PMID: 27378225
IF: 4.909
Q: 1  D: 1

Castón JJ, De la Torre Á, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisneros J. Salvage therapy with ceftolozane/tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2017; 61(3): e02136-16. pii: e02136-16. doi: 10.1128/AAC.02136-16. PMID: 27956431
IF: 4.302
Q: 1  D: 2

Machuca I, Gutiérrez-Gutiérrez B, Gracia-Ahufinger I, Rivera F, Cano Á, Guzmán-Puche J, Pérez-Nadales E, Natera C, Rodríguez M, León R, Castón JJ, Rodríguez-López F, Rodríguez-Baño J, Torre-Cisneros J. Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniaewith high-level meropenem resistance: importance of combination therapy without colistin and carbapenems. Antimicrob Agents Chemother. 2017; 61(8). pii: e00406-17. doi: 10.1128/AAC.00406-17.  PMID: 28559247
IF: 4.302
Q: 1  D: 2

Amat T, Gutiérrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Pérez-Nadales E, Torre-Giménez Á, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The Combined Use of Tigecycline with High-Dose Colistin Might Not be Associated With Higher Survival in Critically ill Patients With Bacteraemia Due to Carbapenem-Resistant Acinetobacter Baumannii. Clin Microbiol Infect. 2018 Jun; 24(6):630-634.  doi: 10.1016/j.cmi.2017.09.016. Epub 2017 Sep 29.  PMID: 28970161
IF: 5,394
Q: 1  D: 1

Cano A, Gutiérrez-Gutiérrez B, Machuca I, Gracia-Ahufinger I, Pérez-Nadales E, Causse M, Castón JJ, Guzman-Puche J, Torre-Giménez J, Kindelán L, Martínez-Martinez L, Rodriguez-Baño J,  Torre-Cisneros J. Risks of infection and mortality among patients colonized with KPC-producing Klebsiella pneumoniae: validation of scores and proposal for management. Clin Infect Dis. 2018 Apr 3; 66(8):1204-1210. doi: 10.1093/cid/cix991. PMID: 29126110
IF: 9,117
Q: 1  D: 1

Páez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortún J, Len O, Abdala E, Fariñas MC, Cordero E, de Gracia C, Hernández D, González R, Torre-Cisneros J, Cantisán S; Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016); Spanish Renal Disease Network (REDinREN, RD16/0009). Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response. Antiviral Res. 2018 Jul; 155: 97-105. doi: 10.1016/j.antiviral.2018.05.006. Epub 2018 May 18. PMID: 29782877
IF: 4,307    
Q: 1  D: 2

AWARDS

  • Premio IMIBIC Best Clinial Research work 2019. Dr Angela Cano Yuste
  • Best in Class Award: Mejor Servicio de Enfermedades Infecciosas: 2015, 2017.
  • Best oral presentation. XIX Congress of the Spanish Society of Infectious Diseases (SAEI) Granada, 14-16 of December 2017: Riesgo de infección y mortalidad en pacientes colonizados por Klebsiella pneumoniae productora de KPC: validación de scores y propuesta de manejo. Ángela Cano Yuste, Belén Gutiérrez-Gutiérrez, Isabel Machuca Sánchez, Irene Gracia-Ahufinger, Elena Pérez-Nadales, Manuel Causse, Juan José Castón, Luís Martínez-Martínez, Jesús Rodríguez-Baño y Julián Torre-Cisneros.

GC03 Infectious Diseases

Principal Investigator
Julián de la Torre Cisneros

Researchers
Sara Cantisán Bohórquez
Juan José Castón Osorio
Elena Pérez Nadales

Post-Doctoral Researchers
Clara Natera Kindelán
José Manuel Rumbao Aguirre
Elisa Vidal Verdú

Pre-Doctoral Researchers
Ángela Cano Yuste
Azahara Frutos Adame
Alejandra Méndez Natera
Aurora Páez Vega
Manuel Recio Rufián
Jorge Valle Arroyo

Administrative Staff
Mª Teresa Añón Gámez
Inmaculada Cantueso Mendez

Technicians
Julian De La Torre Giménez
Ana Salinas Gavilán

Projects

Active projects

Regional

Cantisán Bohórquez, S. IMPLEmentation of Cytomegalovirus Immune monitoring in clinical practice to improve the control of the infection in solid organ transplantation (IMPLICI-TOS). Funding agency: IMIBIC. Reference: PIN-0541-2018.

De la Torre Cisneros, J.Constitución de la Red Andaluza para la realización de ensayos clínicos en enfermedades infecciosas ANCRAID (Andalusian Network for Clinical Research in Infectious Diseases). Funding agency: Regional Ministry of Heatlh. Reference: RIC-0537-2018. End Date: 31/12/2022

National

De la Torre Cisneros, J. Clinical trial to stop valganciclovir prophylaxis in CMV-seropositive renal transplant patients who maintain CD8+ CMV-specific cellular immunity after receiving thymoglobulin. Funding agency: Institute Carlos III Health (ISCIII). Reference: PI15/00402

Cantisán Bohorquez, S. Impact of the lack of CMV-specific CD8+ T cell response in CMV-seropositive donors on CMV reactivation after hematopoietic stem cells transplant in CMV-seropositive recipients. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI15/01419

Perez Nadales, E.  Risk factors for bacterial load of colonization, dissemination to the community, and mortality by arbapenemase-producing Klebsiella pneumoniae (Klebcom Study). Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI16/01631   

De la Torre Cisneros, J. Spanish Network for Research on Infectious Diseases (REIPI). Funding agency: National Institute of Health Carlos III (ISCIII). Reference: RD16/0016/0008    

De la Torre Cisneros, J. Clinical trial of efficacy and safety of the combination of short-duration prophylaxis followed by immunoguided prophylaxis in lung transplant recipients (Cytocor Study). Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI18/00099.

De la Torre Cisneros, J. BECA 2019 PARA LA INVESTIGACIÓN DE LA SATOT: Ensayo clínico de eficacia y seguridad de la combinación de profilaxis de duración reducida seguida de profilaxis inmunoguiada en receptores de trasplante pulmonar (Estudio CYTOCOR).; Funding Agency: SOCIEDAD ANDALUZA DE TRASPLANTES DE ÓRGANOS Y TEJIDOS; Reference: SATOT_2019_001

Castón Osorio, JJ. Ensayo clínico aleatorizado, controlado, para valorar la eficacia del trasplante de microbiota fecal para la descolonización intestinal en pacientes colonizados por Klebsiella Pneumoniae tipo KPC. Funding Agency: National Institute of Health Carlos III (ISCIII). Reference: PI19/00281. End date: 31/12/2022

International

De la Torre Cisneros, J. Combatting Bacterial Resistance in Europe (COMBACTE-NET). Funding Agency: IMI - call 6, 2012, Topic 1: Innovative Trial Design & Clinical Drug Development. Reference: Grant Agreement nr: 115523.

De la Torre Cisneros, J. Combatting Bacterial Resistance in Europe – Carbapenem Resistance (COMBACTE-CARE). Funding Agency: IMI - call 9, 2013, Topic 5: Clinical development of antibacterial agents for Gram-negative antibiotic resistant pathogens. Reference: Grant Agreement nr: 115620.

Castón Osorio, JJ. Impact of the treatment with ceftazidime/avibactam vs best available therapy on mortality of patients with infections caused by carbapenem-resistant Enterobacteriaceae. Funding Agency: PFIZER, S.A.

Publications

Main publications 2019

Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Castón JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Baño J, Torre-Cisneros J. Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 2019. 79. 3. 245-252. DOI: 10.1016/j.jinf.2019.06.014.
IF: 5,099
Q: 1

Machuca I, Gutiérrez-Gutiérrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Pérez E, Pérez-Nadales E, Castón JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual Á, Martínez-Martínez L, Rodríguez-Baño J, Torre-Cisneros J; REIPI/ESGBIS/INCREMENT group. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteremia cohort: The prognostic significance of colistin resistance. Int J Antimicrob Agents. 2019 Oct; 54(4):442-448. doi: 10.1016/j.ijantimicag.2019.07.017. Epub 2019 Aug 1.
IF: 4,615
Q: 1

Ramos-Vivas J, Chapartegui-González I, Fernández-Martínez M, González-Rico C, Fortún J, Escudero R, Marco F, Linares L, Montejo M, Aranzamendi M, Muñoz P, Valerio M, Aguado JM, Resino E, Ahufinger IG, Vega AP, Martínez L, Fariñas MC; ENTHERE Study Group, the Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Biofilm formation by multidrug resistant Enterobacteriaceae strains isolated from solid organ transplant recipients. Sci Rep. 2019 Jun 20; 9(1):8928. doi: 10.1038/s41598-019-45060-y.
IF: 4,011
Q: 1

Tacconelli E, Mazzaferri F, Marie de Smet A, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwaber MJ, Souli M, Torre-Cisneros J, Price JR, Rodríguez-Baño J. ESCMID-EUCIC clinical guidelines on decolonisation of multidrug-resistant Gram-negative bacteria carriers. Clin Microbiol Infect. 2019 Jul; 25(7):807-817. doi: 10.1016/j.cmi.2019.01.005. Epub 2019 Jan 29.
IF: 6,425
Q: 1 D: 1

Fernández-Ruiz M, Giménez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez-Vega A, Cantisán S, Torre-Cisneros J, Fortún J, Andrés A, San Juan R, López-Medrano F, Navarro D, Aguado JM; Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Regular monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect. 2019 Mar; 25(3): 381.e1-381.e10. doi: 10.1016/j.cmi.2018.05.010. Epub 2018 May 25.
IF: 6,425
Q: 1 D: 1

Other publications 2019

Giannella M, Pascale R, Gutiérrez-Gutiérrez B, Cano A, Viale P. The use of predictive scores in the management of patients with carbapenem-resistant Klebsiella pneumoniae infection. Expert Rev Anti Infect Ther. 2019 Mar 15:1-9. doi: 10.1080/14787210.2019.1595590. PMID: 30876375
IF: 3,141
Q: 2

López-Aladid R, Guiu A, Mosquera MM, López-Medrano F, Cofán F, Linares L, Torre-Cisneros J, Vidal E, Moreno A, Aguado JM, Cordero E, Martin-Gandul C, Carratalá J, Sabé N, Niubó J, Cervera C, Capón A, Cervilla A, Santos M, Bodro M, Muñoz P, Fari-ñas MC, Antón A, Aranzamendi M, Montejo M, Pérez-Romero P, Len O, Marcos MÁ. Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next ge-neration sequencing. PLoS One. 2019 Jul 18; 14(7): e0219701. doi: 10.1371/journal.pone.0219701. eCollection 2019. PMID: 31318908
IF: 2,776
Q: 2

Páez-Vega A, Cantisán S, Vaquero JM, Vidal E, Luque-Pineda A, Lobo-Acosta MA, Pérez AB, Alonso-Moralejo R, Iturbe D, Monforte V, Otero-Gonzalez I, Pastor A, Ussetti P, Torre-Cisneros J. Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): An open-label, randomised, non-inferiority clinical trial. BMJ Open. 2019 Aug 15; 9(8): e030648. doi: 10.1136/bmjopen-2019-030648. PMID: 31420397
IF: 2,376
Q: 2

Shepshelovich D, Tau N, Green H, Rozen-Zvi B, Issaschar A, Falcone M, Coussement J, Zusman O, Manuel O, Mor E, Torre-Cisneros J, Yahav D. Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection - a multinational survey. Transpl Infect Dis. 2019 Oct; 21(5): e13134. doi: 10.1111/tid.13134. Epub 2019 Jul 12. PMID: 31242341
IF: 2,112
Q: 3

Sánchez-Fabra D, Dyar OJ, Del Pozo JL, Amiguet JA, Colmenero JD, Fariñas MDC, López-Medrano F, Portilla J, Praena J, Torre-Cisneros J, Rodríguez-Baño J, Pulcini C, Paño-Pardo JR; en representación de ESGAP (ESCMID Study Group for Antimicrobial Stewardship). Perspective of Spanish medical students regarding undergraduate education in infectious diseases, bacterial resistance and antibiotic use. Enferm Infecc Microbiol Clin. 2019 Jan; 37(1):25-30. doi: 10.1016/j.eimc.2017.12.003. Epub 2018 Feb 21. English, Spanish. PMID: 29429753
IF: 1,685
Q: 4

Main publications 2018

Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M, Caston JJ, Guzman-Puche J, Torre-Gimenez J, Kindelan L, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J.Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management. CLINICAL INFECTIOUS DISEASES. 2018; 66(8):1204-1210.
IF:9,117  
Q: 1   D: 1

Amat T, Gutierrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24(6):630-634.
IF: 5,394  
Q: 1   D: 1

Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R, Fernandez-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24:S10-S20.
IF: 5,394  
Q: 1   D: 1

Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S.Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG + response. ANTIVIRAL RESEARCH. 2018; 155:97-105.
IF: 4,307  
Q: 1

Clemente WT, Mourao PHO, Lopez-Medrano F, Schwartz BS, Garcia-Donoso C, Torre-Cisneros J. Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors. TRANSPLANTATION. 2018; 102(2):S8-S15.
IF: 3,96  
Q: 1   D: 1

Other publications 2018

Kumar D, Ferreira VH, Blumberg E, Silveira F, Cordero E, Perez-Romero P, Aydillo T, Danziger-Isakov L, Limaye AP, Carratala J, Munoz P, Montejo M, Lopez-Medrano F, Farinas MC, Gavalda J, Moreno A, Levi M, Fortun J, Torre-Cisneros J, Englund JA, Natori Y, Husain S, Reid G, Sharma TS, Humar A. A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. CLINICAL INFECTIOUS DISEASES. 2018; 67(9):1322-1329.
IF: 9,117  
Q: 1   D: 1

Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24(11):1218-1219.
IF: 5,394  
Q: 1    D: 1

Rivero-Juarez A, Camacho A, Brieva T, Frias M, Lopez-Lopez P, Risalde MA, Machuca I, Caston JJ, Martinez-Peinado A, Rivero A. Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018; 78(4):437-440.
IF: 4,116  
Q: 1

Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, Lopez-Velez R, Cuenca-Estrella M, Torre-Cisneros J, Petersen E, Camargo LFA, Wright AJ, Beeching NJ, Vilela EG, Santoro-Lopes G, Len O, Stucchi RSB, Manuel O, Faria LC, Leblebicioglu H, Huprikar S, Molina I, Mourao PHO, Kotton CN, Aguado JM. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. TRANSPLANTATION. 2018; 102(2):193-208.
IF: 3,96  
Q: 1   D: 1

Torre-Cisneros J, Natera C, Mesa F, Trikic M, Rodríguez-Baño J. Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study. Eur J Clin Microbiol Infect Dis. 2018 Jan; 37(1): 51-56.  doi: 10.1007/s10096-017-3100-y. Epub 2017 Sep 8. PMID: 28887643
IF: 2,537   
Q: 2

Serrano-Alonso M, Guillen-Grima F, Martin-Moreno P, Rabago G, Manrique J, Garcia-del-Barrio M, Reina G, Torre-Cisneros J, Fernandez-Alonso M, Herrero JI. Reduction in mortality associated with secondary cytomegalovirus prophylaxis after solid organ transplantation. TRANSPLANT INFECTIOUS DISEASE. 2018; 20(3): Núm artículo e12873
IF: 1,869  
Q: 3

Aguado JM, Silva JT, Fernández-Ruiz M, Cordero E, Fortún J, Gudiol C, Martínez-Martínez L, Vidal E, Almenar L, Almirante B, Cantón R, Carratalá J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernández J, Fariñas MC, Gavaldà J, Goyanes MJ, Gutiérrez-Gutiérrez B, Hernández D, Len O, López-Andujar R, López-Medrano F, Martín-Dávila P, Montejo M, Moreno A, Oliver A, Pascual A, Pérez-Nadales E, Román-Broto A, San-Juan R, Serón D, Solé-Jover A, Valerio M, Muñoz P, Torre-Cisneros J; Spanish Society of Transplantation (SET); Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC); Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016). Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA/SEIMC/REIPI recommendations. Transplant Rev (Orlando). 2018 Jan; 32(1):36-57.  doi: 10.1016/j.trre.2017.07.001. Epub 2017 Jul 26. Review. PMID: 28811074
IF: 2,364     
Q: 3

Machuca I, Vidal E, Torre-Cisneros J, Rivero-Roman A. Tuberculosis in immunosuppressed patients. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2018;  36(6):366-374.
IF: 1,707  
Q: 3

Guirao-Arrabal E, Torre-Cisneros J. Tuberculin skin test, Interferon gamma release assays or just chest x-ray to study latent tuberculosis before solid organ transplantation? Transpl Infect Dis. 2018 Aug; 20(4): e12920. doi: 10.1111/tid.12920. Epub 2018 Jun 8.  PMID: 29797688
IF: 1,869     
Q: 3

Silva JT, Torre-Cisneros J, Aguado JM. Invasive aspergillosis in solid organ transplantation. REVISTA IBEROAMERICANA DE MICOLOGIA. 2018; 35(4):206-209.
IF: 0,989   Q: 4

Aguado R, Páez-Vega A, Agüera ML, Montejo M, Guirado L, Fortún J, Suárez-Benjumea A, Len O, Fariñas MC, de Gracia C, Hernández D, Cobos-Ceballos MJ, Torre-Cisneros J, Cantisán S; Spanish Network for Research in Infectious Diseases and the Spanish Renal Disease Network; Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients. Hum Immunol. 2018 Jun; 79 (6): 499-505.  doi: 10.1016/j.humimm.2018.03.009. Epub 2018 Mar 29. PMID: 29605690
IF: 1,994  Q: 4

Main publications 2017

Caston JJ, De la Torre A, Ruiz-Camps I, Sorli ML, Torres V, Torre-Cisneros J. Salvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017.61(3):-UNSP e02136-16.
IF: 4,302
Q: 1 

Machuca I, Gutierrez-Gutierrez B, Gracia-Ahufinger I, Espinar FR, Cano A, Guzman-Puche J, Perez-Nadales E, Natera C, Rodriguez M, Leon R, Caston JJ, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017.61(8):-e00406-17.
IF: 4,302
Q: 1

Frías M, Rodriguez-Cano D, Cuenca-Lopez F, Macias J, Gordon A, Manzanares-Martin B, Pineda JA, Camacho A, Torre-Cisneros J, Pena J, Rivero-Juarez A, Rivero A. HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. PHARMACOGENOMICS JOURNAL. 2017. 17(6):551-555.
IF: 3,815
Q: 1 

Frias M, Rodriguez-Cano D, Cuenca-Lopez F, Macias J, Gordon A, Manzanares-Martin B, Pineda JA, Camacho A, Torre-Cisneros J, Pena J, Rivero-Juarez A, Rivero A. HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. PHARMACOGENOMICS JOURNAL. 2017. 17(6):479-480.
IF: 3,815
Q: 1 

Cantisan S, Paez-Vega A, Santos F, Rodriguez-Benot A, Aguado R, Rivero A, Montejo M, Torre-Cisneros J, Solana R. Spanish Network Res Infect Dis. Impact of age and cytomegalovirus on CD8(+) T-cell compartment remodeling after solid organ transplantation: A one-year follow-up study. EXPERIMENTAL GERONTOLOGY. 2017.95():98-106.
IF: 3,34
Q: 1

Guirao-Arrabal E, Santos F, Redel J, Vaquero JM, Torre-Cisneros J. Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. CLINICAL TRANSPLANTATION. 2017. 31(3):-e12901.
IF: 1,865
Q: 2

Rivero A, Perez-Molina JA, Blasco AJ, Arribas JR, Crespo M, Domingo P, Estrada V, Iribarren JA, Knobel H, Lazaro P, Lopez-Aldeguer J, Lozano F, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, de la Torre J, Tuset M, Gatell JM. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2017. 35(2):88-99.
IF: 1,714
Q: 3

Other publications 2017

Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pano-Pardo JR, Venditti M, Tumbarello M, Daikos G, Canton R, Doi Y, Tuon FF, Karaiskos I, Perez-Nadales E, Schwaber MJ, Azap OK, Souli M, Roilides E, Pournaras S, Akova M, Perez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodriguez-Baño J.REIPI ESGBIS INCREMENT. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. LANCET INFECTIOUS DISEASES. 2017. 17(7):726-734.
IF: 19,864
Q: 1    D: 1

Palacios-Baena ZR, Gutierrez-Gutierrez B, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martinez-Martinez L, Pitout J, Akova M, Pena C, Gil-Bermejo JM, Hernandez A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Perez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Pano-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodriguez-Bano J, Spanish Network Res Infect Dis. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. CLINICAL INFECTIOUS DISEASES. 2017.65(10):1615-1623.
IF: 8,216
Q: 1  D: 1

Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavalda J, Moreno A, Torre-Cisneros J, Montejo JM, Fortun J, Munoz P, Sabe N, Farinas MC, Blanes-Julia M, Lopez-Medrano F, Suarez-Benjumea A, Martinez-Atienza J, Rosso-Fernandez C, Perez-Romero P.TRANSGRIPE 1-2 Study Group. Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. CLINICAL INFECTIOUS DISEASES. 2017. 64 (7):829-838.
IF: 8,216
Q: 1   D: 1

Palacios-Baena ZR, Gutierrez-Gutierrez B, De Cueto M, Viale P, Venditti M, Hernandez-Torres A, Oliver A, Martinez-Martinez L, Calbo E, Pintado V, Gasch O, Almirante B, Lepe JA, Pitout J, Akova M, Pena-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origuen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, Perez F, Almela M, Lowman W, Hsueh PR, Francisco CNS, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual A, Rodriguez-Bano J, REIPI ESGBIS INCREMENT Grp. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extendedspectrum- beta-lactamase-producing Enterobacteriaceae. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017. 72(3):906-913.
IF: 5,071
Q: 1

Segorbe D, Di Pietro A, Perez-Nadales E, Turra D. Three Fusarium oxysporum mitogen-activated protein kinases (MAPKs) have distinct and complementary roles in stress adaptation and cross-kingdom pathogenicity. MOLECULAR PLANT PATHOLOGY. 2017. 18 (7):912-924.
IF: 4,697
Q: 1   D: 1

Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jimenez-Martin MJ, Martinez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos JCR, Rodriguez M, Sanchez-Garcia M, Viale P, Wolff M, Carmeli Y. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017. 61(2):-e01964-16.
IF: 4,302
Q: 1 

Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Alvarez R, Maestro-de La Calle G, Cano A, Cervera C, Clemente WT, Martin-Davila P, Freifeld A, Gomez L, Gottlieb T, Gurgui M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M, Rodriguez-Bano J, Ruiz-Camps I, Sukiennik TC, Tebe C, Carratala J.BICAR Study Grp. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017. 61(8):-e00164-17.
IF: 4,302
Q: 1  

Lopez-Aladid R, Guiu A, Sanclemente G, Lopez-Medrano F, Cofan F, Mosquera MM, Torre-Cisneros J, Vidal E, Moreno A, Aguado JM, Cordero E, Martin-Gandul C, Perez-Romero P, Carratala J, Sabe N, Niubo J, Cervera C, Cervilla A, Bodro M, Munoz P, Farinas C, Codina MG, Aranzamendi M, Montejo M, Len O, Marcos MA, Spanish Soc Infect Dis Clinical Mi, Spanish Network Res Infect. Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance. JOURNAL OF CLINICAL VIROLOGY. 2017. 90():57-63.
IF: 3,051
Q: 2

Gudiol C, Royo-Cebrecos C, Tebe C, Abdala E, Akova M, Alvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martin-Davila P, Freifeld A, Gomez L, Gottlieb T, Gurgui M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M, Rodriguez-Bano J, Ruiz-Camps I, Sukiennik TC, Carratala J.BICAR Study Grp. Clinical efficacy of beta-lactam/beta-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). BMJ OPEN. 2017. 7(1):-e013268.
IF: 2,369
Q: 1

Clinical Research

Active in 2019

Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para evaluar la eficacia de fosfomicina vs meropenem en el tratamiento dirigido de la infección urinaria bacteriémica por Escherichia coli productor de betalactamasas de espectr.
PI: Dr. Clara Natera Kindelán

Clinical trial of suspension of prophylaxis with valganciclovir in CMV-seropositive kidney transplant recipients that maintain cellular immunity CMV-specific CD8 + after receiving thymoglobuline.
PI: Dr. Julián de la Torre Cisneros

A Multicenter, Randomized, Open-Label Clinical Study Of S-649266 Or Best Available Therapy For The Treatment Of Severe Infections Caused By Carbapenem-Resistant Gram-Negative Pathogens.
PI: Dr. Julián de la Torre Cisneros

Estudio de fase IIb, comparativo, multicéntrico, aleatorizado, doble ciego, para evaluar la eficacia y seguridad de VIS410 por vía intravenosa administrado junto con oseltamivir (Tamiflu®) en comparación con oseltamivir en monoterapia en adultos hospitalizados con infección por el virus de la gripe A que requieren soporte con oxígeno.
PI: Dr.  Angela M Cano Yuste

Imipenem/Relebactam/Cilastatin versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014).
PI: Dr. Juan José Castón Osorio

Estudio comparativo, aleatorizado, doble ciego, multicéntrico, de la seguridad, tolerabilidad, eficacia y farmacocinética de CF-301 frente a placebo agregado al tratamiento antibacteriano de referencia para el tratamiento de pacientes adultos que padecen sepsis por Staphylococcus aureus (bacteriemia) con endocarditis que afecta al lado derecho.
PI: Dr. Angela M Cano Yuste

Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para  demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por Enterobacteriaceae.
PI: Dr. Juan José Castón Osorio

Un estudio aleatorizado, doble ciego, con control de dosis controlado por placebo evaluando la seguridad, la farmacocinética y el beneficio clínico de la FLU-IGIV en pacientes hospitalizados con infección grave por influenza A.
PI: Dr. Angela M Cano Yuste

A retrospective study to evaluate the epidemology, standar of care, outcomes and resource use associatedwith patiens who have, or rare at risk of, infection with carbapenem non-susceptible (CarbNS) gram-negative organisms of interest (Enterobacteriaceae.
PI: Dr. Julián de la Torre Cisneros

Ensayo clínico de eficacia y seguridad de la combinación de profilaxis de duración reducida seguida de profilaxis inmunoguiada en receptores de trasplante pulmonar.
PI: Dr. Julián de la Torre Cisneros

Estudio de fase III, aleatorizado, con doble enmascaramiento y comparador activo de comparación de la eficacia y la seguridad entre ridinilazol (200 mg, 2 veces/día) durante 10 días y vancomicina (125 mg, 4 veces/día) durante 10 días para el tratamiento d.
PI: Dr. Julián de la Torre Cisneros

Advanced understandign of StaPhylococcus aureus infections in Europe- Surgical site infections (ASPIRE-SSI).
PI: Dr. Julián de la Torre Cisneros

Impacto clínico y microbiológico de los nuevos antipseudomónicos ceftolozano-tazobactam y ceftazidima-avibactam en las infecciones por Psudomonas aeruginosa extremadamente resistente. ESTUDIO PseudoNOVA.
PI: Dr. Elisa Vidal Verdú

Impact of the treatment with ceftazidime/avibactam vs best available therapy on mortality of patients with infections caused by carbapenem-resistant Enterobacteriaceae.
PI: Dr. Juan José Castón Osorio

Eficacia De Fosfomicina Intravenosa En La Infeccion Urinaria Complicada Con Condiciones De Vida Real. Impacto De La Cmi Y De Las Mutaciones Basales.
PI: Dr. Julián Carlos De La Torre Cisneros

Estudio de intervención quiasi-experimental para la optimización del uso de nuevos antibióticos (proyecto new safe).
PI: Dr. Juan José Castón Osorio

Members

Dr. Julián de la Torre Cisneros

Principal Investigator

Team

Sara Cantisán Bohórquez, Juan José Castón Osorio, Elena Pérez Nadales, Clara Natera Kindelán, José Manuel Rumbao Aguirre, Elisa Vidal Verdú, Ángela Cano Yuste, Azahara Frutos Adame, Alejandra Méndez Natera, Aurora Páez Vega, Manuel Recio Rufián, Jorge Valle Arroyo, Mª Teresa Añón Gámez, Inmaculada Cantueso Mendez, Julian De La Torre Giménez, Ana Salinas Gavilán